Optimize Meds for Peripheral Artery Disease

You'll hear debate about how to manage stable peripheral artery disease (PAD)...now that rivaroxaban (Xarelto) is approved for this use.

Think of managing PAD as similar to coronary artery disease...both are due to plaque buildup.

We know PAD patients have a high risk of complications...such as CV events or limb amputation. Plus they may develop symptoms...claudication or pain that reduces walking distance and quality of life.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote